The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine
Tóm tắt
Từ khóa
Tài liệu tham khảo
Herndon, 1998, Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia group B, Chest, 113, 723, 10.1378/chest.113.3.723
Byrne, 1999, Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study, J Clin Oncol, 17, 25, 10.1200/JCO.1999.17.1.25
Kumar-Singh, 1997, Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma, J Pathol, 182, 211, 10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
Gasparini, 2005, Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions, J Clin Oncol, 23, 1295, 10.1200/JCO.2005.10.022
Hanahan, 2000, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice, J Clin Invest, 105, 1045, 10.1172/JCI9872
D’Amato, 1994, Thalidomide is an inhibitor of angiogenesis, Proc Natl Acad Sci USA, 9, 4082, 10.1073/pnas.91.9.4082
Singhal, 2000, Antitumor activity of thalidomide in refractory multiple myeloma, N Engl J Med, 341, 1565, 10.1056/NEJM199911183412102
Ohta, 1999, VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours, Br J Cancer, 81, 54, 10.1038/sj.bjc.6690650
Filho, 2007, Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma, Diagn Cytopathol, 35, 786, 10.1002/dc.20767
Nakano, 1998, Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma, Br J Cancer, 77, 907, 10.1038/bjc.1998.150
Hedman, 2003, Tissue polypeptide antigen (TPA), hyaluronan and CA125 as serum markers in malignant mesothelioma, Anticancer Res, 23, 531
Pettersson, 1988, Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma, Chest, 94, 1037, 10.1378/chest.94.5.1037
Schouwink, 1999, Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma, Lung Cancer, 25, 25, 10.1016/S0169-5002(99)00044-6
Creaney, 2005, Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein, Hematol Oncol Clin North Am, 19, 1025, 10.1016/j.hoc.2005.09.007
Demirag, 2005, Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma, Chest, 128, 3382, 10.1378/chest.128.5.3382
Hashimoto, 2005, The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma, Cancer, 103, 1856, 10.1002/cncr.20976
Nijsten, 1987, Serum levels of interleukin-6 and acute phase responses, Lancet, 2, 921, 10.1016/S0140-6736(87)91413-9
Jones, 2001, The soluble interleukin 6 receptor: mechanisms of production and implications in disease, FASEB J, 15, 43, 10.1096/fj.99-1003rev
Scholler, 1999, Sobuble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma, Proc Natl Acad Sci USA, 96, 11531, 10.1073/pnas.96.20.11531
Beyer, 2007, MESOMARK™: a potential test for malignant pleural mesothelioma, Clin Chem, 53, 666, 10.1373/clinchem.2006.079327
Hollen, 2004, Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation, Cancer, 101, 587, 10.1002/cncr.20315
Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059
Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9
Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145
Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136
Baas, 2005, Thalidomide in patients with malignant pleural mesothelioma, Lung Cancer, 48, 291, 10.1016/j.lungcan.2004.10.005
Baas P. NVALT5 Trial—phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy. Available at: www.trialregister.nl/trialreg/admin/rctview.asp?TC=798; 2006.
Baas, 2010, Open label randomized phase III maintenance study of thalidomide (arm A) vs. observation (arm B) in patients with MPM after treatment with cisplatin and pemetrexed: interim report (abstr S10-2), 135
Lee, 2009, Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial, J Natl Cancer Inst, 101, 1049, 10.1093/jnci/djp200
Pujol, 2007, Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01, J Clin Oncol, 25, 3945, 10.1200/JCO.2007.11.8109
Robinson, 2003, Mesothelin-family proteins and diagnosis of mesothelioma, Lancet, 362, 1612, 10.1016/S0140-6736(03)14794-0
Karrison, 2007, Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM), J Clin Oncol, 25, 7526, 10.1200/jco.2007.25.18_suppl.7526
Dowlati, 2008, Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Oncology Group study, Clin Cancer Res, 14, 1407, 10.1158/1078-0432.CCR-07-1154
Poon, 2001, Clinical implications of circulating angiogenic factors in cancer patients, J Clin Oncol, 19, 1207, 10.1200/JCO.2001.19.4.1207
George, 2000, Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?, Clin Cancer Res, 6, 3147
Lee, 2000, Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?, Int J Oncol, 17, 149
Pinedo, 1998, Involvement of platelets in tumour angiogenesis?, Lancet, 352, 1775, 10.1016/S0140-6736(98)05095-8
Verheul, 1997, Platelet: transporter of vascular endothelial growth factor, Clin Cancer Res, 3, 2187
Wynendaele, 1999, Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?, Ann Oncol, 10, 965, 10.1023/A:1008377921886
Hormbrey, 2002, A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?, Clin Exp Metastasis, 19, 651, 10.1023/A:1021379811308
Ganapathi, 1988, Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines, Biochem Biophys Res Commun, 157, 271, 10.1016/S0006-291X(88)80043-3
Jones, 1999, C-reactive protein: a physiological activator of interleukin 6 receptor shedding, J Exp Med, 189, 599, 10.1084/jem.189.3.599
McKeown, 2004, The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer, Br J Cancer, 19, 1993, 10.1038/sj.bjc.6602248
Jones, 2002, The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex, Biochim Biophys Acta, 1592, 251, 10.1016/S0167-4889(02)00319-1